HOME >> BIOLOGY >> NEWS
Novel Two-Antibody Strategy To Fight Cancer Awarded Patent

Researchers at the University of Pennsylvania Medical Center today were awarded patent number 5,824,311 for a new technology that has shown the potential in laboratory studies to cure breast and other major cancers linked to certain abnormal genes.

Broadly viewed, the approach targets cancer-causing receptor molecules found on the surface of tumor cells with two different antibodies that bind to the molecules, fatally disabling the receptor's activity and leading to the cancer cell's death.

The specific application of the concept detailed in the patent employs a pair of antibodies against a receptor protein called p185. The p185 protein assembles into a two-protein receptor complex thought to be involved in stimulating the uncontrolled growth of a number of dangerous cancers, including those of the breast and the pancreas. Instructions for producing the p185 protein in the cell are encoded by a gene known as neu.

The recently approved anti-breast-cancer drug Herceptin also acts on the receptor produced by the neu gene but brings only one antibody to bear on it. Experiments in rodent models, however, showed that a two-antibody strategy was significantly more powerful.

"In our two-antibody studies, we were able to achieve cures of tumors as opposed to simply reducing tumor growth," says Mark I. Greene, MD, PhD, a professor of pathology and laboratory medicine in whose laboratory the work was conducted. "In our experience, a single antibody against the receptor only diminishes the growth of tumor cells, whereas two antibodies disable the receptor so effectively that the cells perish."

Receptor proteins are convoluted structures with many sites -- called epitopes -- to which a wide array of antibodies can bind. It is possible for some of these sites not to be involved in the activity of the protein. Also, antibodies that bind in different ways to the same site can limit each other's effectiveness. Signif
'"/>

Contact: Franklin Hoke
hokef@mail.med.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
20-Oct-1998


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
Breaking Biology Technology:
Cached News: